Abstract
Treatment of 5q- myelodysplastic syndrome (MDS) with single agent lenalidomide therapy eliminates hematologic and cytogenetic abnormalities resulting in decreased transfusion requirements (
NEJM
2005
; 352
(6):549
–557NEJM
2005
; 352
(6):549
–557Author notes
Disclosure: No relevant conflicts of interest to declare.
2007, The American Society of Hematology
2007
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal